Alnylam Pharmaceuticals
ALNY
193 hedge funds and large institutions have $3.68B invested in Alnylam Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 75 increasing their positions, 68 reducing their positions, and 34 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
10% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 68
1% less capital invested
Capital invested by funds: $3.73B → $3.68B (-$50.2M)
2% less funds holding
Funds holding: 197 → 193 (-4)
11% less call options, than puts
Call options by funds: $37.3M | Put options by funds: $41.7M
12% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 34
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$104M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.6M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$37M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$35.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.4M |
Top Sellers
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$53.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$21.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.4M |
| 4 |
CCI
Columbus Circle Investors
|
-$16.9M |
| 5 |
DM
Deerfield Management
New York
|
-$12M |
ALNY Hedge Fund Activity: Q2 2014 in Review
193 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2014, worth a combined $3.68B — down 1.3% from $3.73B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ALNY and 30 opened new positions — a net loss of 4 holders — while 68 trimmed existing stakes and 75 added.
The largest buyer was Fidelity Investments, adding an estimated $104M. The largest seller was BlackRock Fund Advisors, cutting an estimated $53.6M.
- 193 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2014, down from 197 in Q1 2014.
- Funds reported $3.68B of Alnylam Pharmaceuticals stock for Q2 2014, down 1.3% quarter-over-quarter.
- 30 funds opened new Alnylam Pharmaceuticals positions in Q2 2014 and 34 closed out, a net change of -4 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2014 was Fidelity Investments, an estimated $104M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2014 was BlackRock Fund Advisors, an estimated $53.6M sold.
Based on aggregated 13F filings for Q2 2014.